Changes in QuantiFERON® -TB Gold in-Tube results during treatment for tuberculous infection

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 7, 2013, Pages 909-916

  Bastos, M L ^a,b   Menzies, D ^c   Belo, M T C T ^a,b,d   Teixeira, E G ^a,b,d   De Abreu, S T ^e   Antas, P R Z ^f   Trajman, Anete ^a,b,c  

^a GAMA FILHO UNIVERSITY   (Brazil)

^b Rio de Janeiro Tuberculosis Scientific League   (Brazil)

^c MCGILL UNIVERSITY   (Canada)

^d Souza Marques Foundation   (Brazil)

^e Paschoal Granato Laboratory   (Brazil)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Biomarker; Interferon gamma assay; Latent tuberculosis; Serial testing

Indexed keywords

GAMMA INTERFERON; ISONIAZID; RIFAMPICIN;

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOLOGY TEST KIT; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULIN TEST;

ADULT; ANTITUBERCULAR AGENTS; BRAZIL; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RIFAMPIN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST; YOUNG ADULT;

EID: 84878946837     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0927     Document Type: Article

References (42)

1. Denkinger C M, Dheda K, Pai M. Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011; 17: 806-814.
2. Hill P C, Brookes R H, Fox A, et al. Longitudinal assessment of an ELISpot test for Mycobacterium tuberculosis infection. PLoS Med 2007; 4: e192.
3. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 2006; 174: 349-355. (Pubitemid 44156616)
4. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 2007; 7: 428-438. (Pubitemid 46779096)
5. Pai M, O'Brien R. Serial testing for tuberculosis: can we make sense of T-cell assay conversions and reversions? PLoS Med 2007; 4: e208.
6. Veerapathran A, Joshi R, Goswami K, et al. T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PLoS ONE 2008; 3: e1850.
7. Metcalfe J Z, Cattamanchi A, McCulloch C E, Lew J D, Ha N P, Graviss E A. Test variability of the Quantiferon-TB Gold In-Tube assay in clinical practice. Am J Respir Crit Care Med 2012; 26: 26.
8. Doberne D, Gaur R L, Banaei N. Preanalytical delay reduces sensitivity of QuantiFERON-TB Gold In-Tube assay for detection of latent tuberculosis infection. J Clin Microbiol 2011; 49: 3061-3064.
9. Detjen A K, Loebenberg L, Grewal H M, et al. Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol 2009; 16: 1170-1175.
10. Whitworth W C, Hamilton L R, Goodwin D J, et al. Withinsubject interlaboratory variability of QuantiFERON-TB Gold In-Tube tests. PLoS ONE 2012; 7: 6.
11. Ewer K, Millington K A, Deeks J J, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after pointsource exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 174: 831-839. (Pubitemid 44511666)
12. Pathan A A, Wilkinson K A, Klenerman P, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T-cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001; 167: 5217-5225. (Pubitemid 33009758)
13. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T-cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004; 38: 754-756. (Pubitemid 38333874)
14. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Transitional changes in T-cell responses to Mycobacterium t uberculosis-specific antigens during treatment. J Infect 2009; 58: 197-204.
15. Chee C B, KhinMar K W, Gan S H, Barkham T M, Pushparani M, Wang Y T. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 2007; 175: 282-287. (Pubitemid 46203133)
16. Komiya K, Ariga H, Nagai H, et al. Reversion rates of Quanti- FERON-TB Gold are related to pre-treatment IFN-gamma levels. J Infect 2011; 63: 48-53.
17. Al-Attiyah R, Mustafa A S, Abal A T, Madi N M, Andersen P. Restoration of mycobacterial antigen-induced proliferation and interferon-gamma responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy. FEMS Immunol Med Microbiol 2003; 38: 249-256. (Pubitemid 37289749)
18. Ulrichs T, Anding P, Kaufmann S H E, Munk M E. Numbers of IFN-γ-producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy. Int J Tuberc Lung Dis 2000; 4: 1181-1183. (Pubitemid 32046299)
19. Stuart R L, Olden D, Johnson P D R, et al. Effect of anti-tuberculosis treatment on the tuberculin interferon-γ response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis. Int J Tuberc Lung Dis 2000; 4: 555- 561.
20. Pai M, Joshi R, Bandyopadhyay M, et al. Sensitivity of a wholeblood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment. Infection 2007; 35: 98-103. (Pubitemid 46536774)
21. Dyrhol-Riise A M, Gran G, Wentzel-Larsen T, Blomberg B, Haanshuus C G, Morkve O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERONTB Gold In-Tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 2010; 10: 57.
22. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008; 13: 468-472. (Pubitemid 351503140)
23. Pai M, Joshi R, Dogra S, et al. Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 2006; 1: 7.
24. Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009; 13: 84-92.
25. Epstein M D, Schluger N W, Davidow A L, Bonk S, Rom W N, Hanna B. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1998; 113: 379-386. (Pubitemid 28110014)
26. Hesseling A C, Walzl G, Enarson D A, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis 2010; 14: 560-570.
27. Wallis R S, Wang C, Doherty T M, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2010; 10: 68-69.
28. Wallis R S, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-1937.
29. Programa Nacional de Controle da Tuberculose, Brazil. Manual de Recomendações para o Controle da Tuberculose no Brasil . Brasilia, Brazil: Ministério da Saùde, 2010. http://portal.saude. gov.br/portal/arquivos/pdf/manual-de-recomendacoes-t.pdf Accessed April 2013. [Portuguese]
30. Cellestis . QuantiFERON® -TB Gold In-Tube package insert. Carnegie, VIC, Australia: Cellestis, 2009. http://www.cellestis. com/IRM/Company/ShowPage. aspx? CPID =1171 Accessed April 2013.
31. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of QuantiFERON-TB Gold In-Tube assay. Clin Vaccine Immunol 2008; 15: 425-432. (Pubitemid 351967072)
32. van Zyl-Smit R N, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS ONE 2009; 4: e8517.
33. Park J S, Lee J S, Kim M Y, et al. Monthly follow-ups of interferon-gamma release assays among healthcare workers in contact with TB patients. Chest 2012; 142: 1461-1468.
34. Santin M, Munoz L, Rigau D. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PloS ONE 2012; 7: 5.
35. Trajman A, Long R, Zylberberg D, Dion M J, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis 2010; 14: 551-559.
36. Wilkinson K A, Kon O M, Newton S M, et al. Effect of treatment of latent tuberculosis infection on the T-cell response to Mycobacterium tuberculosis antigens. J Infect Dis 2006; 193: 354-359. (Pubitemid 43122334)
37. Cellestis. Validation report QuantiFERON® -TB Gold In-Tube: reproducibility study . R06Q4-01. Carnegie, VIC, Australia: 2006. http://www.cellestis.com/IRM/Company/ShowPage. aspx/PDFs/1359-10000000/ ValidationReportQFTInTube ReproducibilityStudy Accessed May 2013.
38. Shin S S, Gallardo M, Lozada R, et al. Cigarette-smoking intensity and interferon-gamma release assay conversion among persons who inject drugs: a cohort study. Pulm Med 2012; 828106: 10.
39. Ringshausen F C, Nienhaus A, Schablon A, Schlosser S, S chultze-Werninghaus G, Rohde G. Predictors of persistently positive Mycobacterium tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis 2010; 10: 220.
40. Shah M, DiPietro D, Greenbaum A, et al. Programmatic impact of QuantiFERON-TB Gold In-Tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic. PloS ONE 2012; 7: 7.
41. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697.
42. Bastos M L, Belo M T C, Silva A P, et al. Factors associated with latent tuberculosis therapy completion in Rio de Janeiro, Brazil [Abstract]. 17th Annual Conference of The Union-North American Region, Vancouver, BC, Canada, 28 February-2 March 2013. http://www.bc.lung.ca/association-and-services/ documents/2013TheUnion-NARPreliminaryProgram-FINAL PROGRAM.pdf Accessed May 2013.